-
Novartis Pharmaceuticals Corporation et al v. Alvogen Pine Brook Inc. et al DC
- 1:13-cv-00052
- D. Del.
- Judge: Richard G. Andrews
- Filed: 01/04/2013
- Closed: 07/07/2014
- Latest Docket Entry: 07/09/2014
- PACER
- Docket updated daily
5
Plaintiffs
2
Defendants
1
Accused
Product
2
Patents-in-Suit
550
Days in
Litigation
-
Novartis Pharmaceuticals Corporation et al v. Alvogen Pine Brook Inc. et al DC
- 1:13-cv-00052
- D. Del.
- Judge: Richard G. Andrews
- Filed: 01/04/2013
- Closed: 07/07/2014
- Latest Docket Entry: 07/09/2014
- PACER
- Docket updated daily
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Alvogen Group Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system | US 6,316,023 B1 | All Asserted Claims |
No infringement
Entry 172Entry 179 |
| 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system | US 6,335,031 B1 | All Asserted Claims |
No infringement
Entry 172Entry 179 |
Alvogen Pine Brook Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system | US 6,316,023 B1 | All Asserted Claims |
No infringement
Entry 172Entry 179 |
| 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system | US 6,335,031 B1 | All Asserted Claims |
No infringement
Entry 172Entry 179 |
